HLA-C and neoplasm: Bispecific antibodies (BsAbs), such as Bi-specific T-cell engagers (BiTEs), bridge T cells to tumour cells by targeting CD3 on T cells and tumour-associated antigens, thereby facilitating tumour cell elimination independent of MHC restriction [384].